| Tocilizumab prophylaxis for patients treated with teclistamab: a single-center experience A Kowalski, JL Lykon, B Diamond, D Coffey, M Kaddoura, F Maura, ... Blood 142, 4709, 2023 | 11 | 2023 |
| High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis J Zhao, JP Bewersdorf, S Jaszczur, A Kowalski, S Perreault, M Schiffer, ... Leukemia & Lymphoma 62 (5), 1195-1202, 2021 | 11 | 2021 |
| T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape D Kazandjian, A Kowalski, O Landgren Leukemia & lymphoma 63 (13), 3032-3043, 2022 | 9 | 2022 |
| Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer? S Agarwal, A Kowalski, M Schiffer, J Zhao, JP Bewersdorf, AM Zeidan Expert Review of Hematology 14 (2), 199-210, 2021 | 9 | 2021 |
| Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome O Megherea, C Janes, A Kowalski, J Baron, E Ahn, A Soule, M Newman Leukemia & Lymphoma 62 (13), 3219-3225, 2021 | 1 | 2021 |
| Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis. M Schiffer, A Kowalski, J Zhao, JP Bewersdorf, RS Lewis Jr, AM Zeidan Drugs of Today (Barcelona, Spain: 1998) 56 (12), 755-768, 2020 | 1 | 2020 |
| Selinexor, Venetoclax, and Dexamethasone in t (11; 14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study) D Kazandjian, K Koubek, A Kowalski, S Mompoint, R Bukhari, M Wilson, ... Blood 144, 7049, 2024 | | 2024 |
| Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab A Kowalski, J Lykon, B Diamond, DG Coffey, M Kaddoura, F Maura, ... Blood 144, 932, 2024 | | 2024 |
| Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma A Kowalski, DG Coffey, B Diamond, JE Hoffman, M Kaddoura, J Lykon, ... Blood 144, 2389, 2024 | | 2024 |
| Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell–Engaging Cancer Therapies A Kowalski, J Lykon, B Diamond, DG Coffey, M Kaddoura, F Maura, ... Blood cancer discovery 5 (2), 90-94, 2024 | | 2024 |
| Assessment of High-Dose Methotrexate Management Guideline in Adults with Cancer at an Academic Medical Center. A Kowalski, SM Jaszczur, M Nadeau-Nguyen, MY Merl Journal of Hematology Oncology Pharmacy 11 (2), 2021 | | 2021 |
